Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Neuromodulation Market, by Technology
1.4.2 Europe Neuromodulation Market, by Biomaterial
1.4.3 Europe Neuromodulation Market, by Application
1.4.4 Europe Neuromodulation Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Approvals and Trials
3.2.3 Product Launches and Product Expansions
3.2.4 Acquisition and Mergers
3.2.5 Geographical Expansions
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
Chapter 4. Europe Neuromodulation Market by Technology
4.1 Europe Internal Market by Country
4.2 Europe External Market by Country
Chapter 5. Europe Neuromodulation Market by Biomaterial
5.1 Europe Metallic Market by Country
5.2 Europe Polymeric Market by Country
5.3 Europe Ceramic Market by Country
Chapter 6. Europe Neuromodulation Market by Application
6.1 Europe Chronic Pain Market by Country
6.2 Europe Urinary & Fecal Incontinence Market by Country
6.3 Europe Migraine Market by Country
6.4 Europe Failed Back Syndrome Market by Country
6.5 Europe Parkinson Disease Market by Country
6.6 Europe Epilepsy Market by Country
6.7 Europe Tremor Market by Country
6.8 Europe Depression Market by Country
6.9 Europe Others Market by Country
Chapter 7. Europe Neuromodulation Market by Country
7.1 Germany Neuromodulation Market
7.1.1 Germany Neuromodulation Market by Technology
7.1.2 Germany Neuromodulation Market by Biomaterial
7.1.3 Germany Neuromodulation Market by Application
7.2 UK Neuromodulation Market
7.2.1 UK Neuromodulation Market by Technology
7.2.2 UK Neuromodulation Market by Biomaterial
7.2.3 UK Neuromodulation Market by Application
7.3 France Neuromodulation Market
7.3.1 France Neuromodulation Market by Technology
7.3.2 France Neuromodulation Market by Biomaterial
7.3.3 France Neuromodulation Market by Application
7.4 Russia Neuromodulation Market
7.4.1 Russia Neuromodulation Market by Technology
7.4.2 Russia Neuromodulation Market by Biomaterial
7.4.3 Russia Neuromodulation Market by Application
7.5 Spain Neuromodulation Market
7.5.1 Spain Neuromodulation Market by Technology
7.5.2 Spain Neuromodulation Market by Biomaterial
7.5.3 Spain Neuromodulation Market by Application
7.6 Italy Neuromodulation Market
7.6.1 Italy Neuromodulation Market by Technology
7.6.2 Italy Neuromodulation Market by Biomaterial
7.6.3 Italy Neuromodulation Market by Application
7.7 Rest of Europe Neuromodulation Market
7.7.1 Rest of Europe Neuromodulation Market by Technology
7.7.2 Rest of Europe Neuromodulation Market by Biomaterial
7.7.3 Rest of Europe Neuromodulation Market by Application
Chapter 8. Company Profiles
8.1 Medtronic PLC
8.1.1 Company overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expenses
8.1.5 Recent strategies and developments:
8.1.5.1 Product Launches and Product Expansions:
8.1.5.2 Acquisition and Mergers:
8.2 LivaNova PLC
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental and Regional Analysis
8.2.4 Research & Development Expense
8.2.5 Recent strategies and developments:
8.2.5.1 Partnerships, Collaborations, and Agreements:
8.2.5.2 Approvals and Trials:
8.3 Boston Scientific Corporation
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental and Regional Analysis
8.3.4 Research & Development Expense
8.3.5 Recent strategies and developments:
8.3.5.1 Geographical Expansions:
8.4 Abbott Laboratories
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental and Regional Analysis
8.4.4 Research & Development Expense
8.4.5 Recent strategies and developments:
8.4.5.1 Product Launches and Product Expansions:
8.5 Nevro Corporation
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Regional Analysis
8.5.4 Research & Development Expense
8.5.5 Recent strategies and developments:
8.5.5.1 Approvals and Trials:
8.6 NeuroSigma, Inc.
8.6.1 Company Overview
8.6.2 Recent strategies and developments:
8.6.2.1 Partnerships, Collaborations, and Agreements:
8.7 NeuroPace, Inc.
8.7.1 Company Overview
8.7.2 Recent Strategies and Developments:
8.7.2.1 Product Launches and Product Expansions:
8.8 Neuronetics, Inc.
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Regional Analysis
8.8.4 Research & Development Expense
8.9 MicroTransponder Inc.
8.9.1 Company Overview
8.9.2 Recent strategies and developments:
8.9.2.1 Approvals and Trials:
8.10. Bioventus Inc.
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Regional Analysis
8.10.4 Research & Development Expenses
8.10.5 Recent strategies and developments:
8.10.5.1 Approvals and Trials:
8.10.5.2 Acquisition and Mergers:
Unique Offerings 
